article thumbnail

Abbott Enters IVL Burgeoning Segment

CardiacWire

IVL is a minimally invasive medical catheter-based procedure that treats calcified plaque in blood vessels. The Takeaway Shockwave might have a decade head start, but it appears that the cardio-medtech industry has woken up to the potential of IVL, and this much competition is likely to breed innovation that benefits patients.

Plaque 59
article thumbnail

Philips Enrolls First Patient in Clinical Trial for Integrated Single-Device to Treat PAD

DAIC

THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter that integrates two critical PAD treatments into a single device. The innovative feature of the Philips catheter is that both the atherectomy and lithotripsy are laser-driven. clinical trial,” said Dr.

article thumbnail

Detection of arterial remodeling using epicardial adipose tissue assessment from CT calcium scoring scan

Frontiers in Cardiovascular Medicine

PR was defined as an outer vessel diameter at least 10% greater than the average diameter of the segments immediately proximal and distal to the plaque. MethodsWe analyzed data from 1,324 patients who underwent both CTCS and CT angiography. Furthermore, our model effectively predicted MACE, with a hazard ratio (HR) of 4.5 [95%

article thumbnail

Roche's Lp(a) Gen.2 Molarity Assay Receives FDA Clearance

DAIC

Roche has an unrivaled ability to provide access to testing at scale and is committed to advancing innovation in preventive cardiology. More than 90% of the Lp(a) level is influenced by variations in the genes controlling the Lp(a) particle production, 2 in which lifestyle interventions such as diet and exercise have no significant impact.

article thumbnail

Simpson Interventions Receives FDA Breakthrough Device Designation for Acolyte Image Guided Crossing and Re-Entry Catheter System

DAIC

We are committed to advancing the field of interventional cardiology and improving patient outcomes through innovation." This designation expedites the development, assessment, and review process, enabling patients to gain access to innovative medical technologies more quickly.

article thumbnail

New research finds ketogenic diet-induced high cholesterol does not predict heart disease

Medical Xpress - Cardiology

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, in collaboration with researchers across multiple institutions, has published a new study that challenges the long-held belief that high cholesterol correlates and even directly causes coronary artery disease, or plaque buildup in the arteries in metabolically healthy (..)

article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

The breakthrough designation, according to the Milpitas, CA-based technology company, is for an indication to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. of the U.S. population.